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A B S T R A C T
Pseudomonas stutzeri is infrequently isolated from clinical specimens, and if isolated, more likely
represents colonization or contamination rather than infection. Despite this, there are dozens of case
reports which describe clinically signiﬁcant P. stutzeri infections at variable sites. A 69-year-old man had a
P. stutzeri infection of a prosthetic vascular graft infection, which he received in Panama City. He was
successfully treated with a single antipseudomonal agent for 6 weeks and the removal of the infected
vascular graft. A 70-year-old man had a P. stutzeri infection of a prosthetic joint, which was successfully
treated with a single anti-pseudomonal agent for 6 weeks. There is only one other documented case of a
prosthetic vascular graft infection secondary to P. stutzeri. There are 5 documented cases of P. stutzeri
prosthetic joint infections. The previous cases were treated with antibiotics and variably, source control
with the removal of prosthetic material. Most cases of P. stutzeri infection are due to exposure in health
care settings. Immunocompromised states such as HIV or hematological and solid tumor malignancies
are risk factors for P. stutzeri infection. Infections caused by P. stutzeri are far less frequent and less fatal
than those caused by P. aeruginosa. The etiology of a P. stutzeri infection could be exposure to soil and
water, but also contaminated material in the health care setting or an immunocompromised state.
Iatrogenic infections that are secondary to health care tourism are a potential cause of fever in the
returned traveler.
ã 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Pseudomonas stutzeri, ﬁrst discovered by Burri and Stutzer in
1895 [1], is an aerobic, ﬂagellated, gram-negative bacterium that is
non-lactose fermenting and oxidase-positive [2]. It is normally
found in soil and water [2].
The organism is infrequently isolated from clinical specimens,
and if isolated, more likely represents colonization or contamination
rather than infection. For example, in a case series of 36 isolates of P.
stutzeri from1977 to 1993 in a Kentucky hospital, 33 were thought to
be secondary to colonization or contamination [3].
The most recent case series of P. stutzeri reported 93 isolates
from 2000 to 2010 in an Israeli hospital [4]. During the study
period, incidence of isolation increased, with more than a third
isolated during the last year of the study period. Despite this* Corresponding author.
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by the 9971 isolates of other Pseudomonas species detected during
the same period, the vast majority of which were P. aeruginosa. In
the same study, P. stutzeri was most frequently isolated from urine
(31%), wounds (28%), and blood (19%). Ten deaths (11%) occurred,
of which 8 were attributable to a signiﬁcant comorbidity rather
than to the P. stutzeri infection itself. In contrast, P. aeruginosa
bacteremia demonstrated a mortality rate of 39% [5].
Despite itsrarityand low riskofmortality, there aredozens ofcase
reports which describe clinically signiﬁcant P. stutzeri infections at a
variety of sites. We present here two such P. stutzeri infections – one
of a prosthetic vascular graft and the other of a prosthetic joint.
Cases
Case 1: prosthetic vascular graft infection
A 69-year-old man with a past medical history signiﬁcant for
atrial ﬁbrillation, asthma, and prior Dengue fever, presented to a
Tropical Medicine Clinic in Toronto, Canada with a several-weekC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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context of having returned from Panama City, Panama about
8 weeks before. In Panama, he was found to have a left internal iliac
artery aneurysm and thrombus which required insertion of a 15-
cm arterial graft. Investigations for endemic infections, including
malaria, typhoid fever, and Dengue fever, were negative. However,
two of two blood cultures drawn on presentation were positive for
P. stutzeri and he was therefore admitted to hospital for further
management. Both P. stutzeri isolates were susceptible to
ceftazidime, ciproﬂoxacin, gentamicin, piperacillin, and tobramy-
cin, but resistant to trimethroprim-sulfamethoxazole. He was
therefore given ceftazidime 2 g intravenously every 8 h as therapy
for his bacteremia. CT angiography of his abdomen and pelvis
demonstrated signiﬁcant perigraft soft tissue density attenuation
suspicious for infection (Fig. 1A).
He subsequently underwent surgical removal of the vascular
graft, embolization of the left internal iliac artery, and insertion of a
left to right femoral–femoral bypass graft. All three specimens
collected intraoperatively grew P. stutzeri with the aforementioned
sensitivity proﬁle. A transthoracic echocardiogram demonstrated a
5 mm mobile echodensity on the ventricular side of the aortic
valve; however, a transesophageal echocardiogram characterized
the echodensity as a degenerative strand. He completed a total of
6 weeks of ceftazidime therapy. At a 6-week follow-up appoint-
ment in an Infectious Diseases clinic, there was no evidence of
infection. A repeat CT of the abdomen and pelvis did not
demonstrate any residual infection (Fig. 1B). A repeat transthoracic
echocardiogram did not demonstrate the abovementioned echo-
density and there was no signiﬁcant aortic insufﬁciency.
Case 2: prosthetic joint infection
A 70-year-old man with a past medical history signiﬁcant for
atrial ﬁbrillation, type 2 diabetes mellitus, and surgically treated
renal cell carcinoma, suffered a right lower extremity fracture
about 3 years before presentation. The fracture was initially treated
with a tibio-talo-calcaneal fusion but was complicated by two
hardware infections in the subsequent 2 years, the ﬁrst of which
did not yield a microbiological diagnosis and the second of which
was due to coagulase-negative Staphylococcus (CNST), requiring
hardware removal and prolonged courses of antimicrobial therapy.
About 3 months after his second infection, he experienced
recurrent pain and drainage from the incision site. An X-ray of his
right foot demonstrated hindfoot arthrodesis with ﬁbular osteot-
omy. He underwent surgical irrigation and debridement of the
infected tibial bone, insertion of a local bone graft, and revision of
the previously performed fusions. Intra-operative cultures fromFig. 1. CT angiography axial slices of the patient with the Pseudomonas stutzeri prosthetic
retroperitoneal soft tissue inﬂammatory changes around the left common iliac prosthetic
graft, demonstrating marked reduction of the retroperitoneal inﬂammatory changes. Tthe tibia grew P. stutzeri sensitive to ceftazidime, ciproﬂoxacin,
gentamicin, piperacillin, tobramycin, and trimethoprim-sulfa-
methoxazole. He was treated with ceftazidime 2 g intravenously
every 8 h. He completed a total of 6 weeks of antimicrobial therapy
and at a 2-month follow-up, his surgical site demonstrated
evidence of healing without any sign of drainage or infection.
Discussion
We present here two rare cases of P. stutzeri prosthetic device
infection in the setting of healthcare facility exposure. Although P.
stutzeri is a saprophyte found in soil, groundwater, marine water,
and salt marshes [2], most cases of P. stutzeri infection are due to
exposure in health care settings. During the 1970s and 1980s, P.
stutzeri caused several outbreaks in the health care setting as a
consequence of environmental contamination. Namely, 3 cases of
bacteremia were secondary to contaminated bottles of intravenous
ﬂuids [6]; 6 cases of bacteremia were secondary to contaminated
deionized water that constituted the dialysate for hemodialysis
[7]; and 24 cases of bacteremia were secondary to contaminated
aqueous green soap used to prepare skin for intravenous insertions
[8]. Thus it is plausible that our patient with a vascular graft
infection acquired a P. stutzeri infection in an acute health care
facility in Panama. Accordingly, it is important to not only consider
endemic, but also nosocomial infections as a cause for fever in a
returned traveler. This is especially important considering the
increasing rates of health care tourism and expatriates seeking
medical care outside of North America [9].
With respect to commonly cited risk factors for P. stutzeri
infection, several case reports have been documented in patients
with immunocompromised states such as HIV or hematological
and solid tumor malignancies. For example, a recent report
described a patient with Crohn’s disease who developed P. stutzeri
meningitis 10 days after the initiation of vedolizumab, a tumor
necrosis factor antagonist [10]. Notably, our patient with a
prosthetic joint infection had a history of renal cell carcinoma
requiring nephrectomy 1 month prior to his admission and type
2 diabetes mellitus, both of which are known to confer an
immunocompromised state. As well, this patient had a preceding
CNST infection, which raises the possibility of the P. stutzeri
infection opportunistically developing in the setting of previous
broad spectrum antimicrobial treatment, as is often the case with
Pseudomonas aeruginosa [11]. Additionally, a recent case of a
necrotizing pneumonia caused by P. stutzeri developed in a patient
with pulmonary tuberculosis [12] and was hypothesized to have
been facilitated by parenchymal destruction caused by Mycobac-
terium tuberculosis. This supports the notion that P. stutzeri left iliac artery graft infection. A. Image before removal of the graft, demonstrating
 graft, with extension into the left psoas muscle (star). B. Image after removal of the
here is interval thrombosis of the left common iliac artery (arrow).
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although no rigorous data investigating this hypothesis is available.
Our ﬁrst case is only the second documented case of a
prosthetic vascular graft infection secondary to P. stutzeri. The ﬁrst
was a 61-year-old woman who received an aorto-bifemoral
vascular graft for an abdominal aortic aneurysm [13].
The possibility of infective endocarditis was raised in our
patient due to the ﬁnding of a possible vegetation on his aortic
valve on echocardiography, although he had a low pre-test
probability of the disease. There are 2 previous case reports of
infective endocarditis secondary to P. stutzeri [14,15]. In a patient
with P. stutzeri bacteremia, we believe that echocardiography is
appropriate in patients with risk factors for infective endocarditis.
The decision to pursue echocardiography may be clinically
signiﬁcant as it would inform the duration of antimicrobial
therapy in cases where shorter courses are sought, and may inform
whether cardiac surgery should be pursued.
Our second case is also a rare example of P. stutzeri prosthetic
joint infection. There are 5 documented cases of P. stutzeri joint
infections [3,16–19], 3 of which were in native joints and 2 in
prosthetic joints. Most of the cases had identiﬁable risk factors for a
joint infection, including a foreign body (1), immunological
deﬁciency (1), and anatomical abnormality (1). In each of two
case series of 93 and 114 isolates, respectively, only 2 were from
synovial ﬂuid [4,20].
Treatments of the abovementioned P. stutzeri joint infections
were variable with respect to the identity and duration of
antimicrobials, and whether or not surgical intervention was
pursued. Deﬁnitive therapy included one or a combination of
6 antimicrobials for a duration of 2 to 8 weeks. Of the 3 native joint
infections, 1 was treated with surgical intervention (total hip
arthroplasty). Of the 2 prosthetic joint infections, 1 was treated
with surgical intervention (total hip arthroplasty). Despite the
variability in treatment, outcomes were good for all cases, except
one case with an infected left prosthetic hip joint treated with
antimicrobials and total hip arthroplasty that presented with
persistent purulent drainage from the wound. Although there is no
literature systematically describing the treatment of joint infec-
tions secondary to P. stutzeri, ours and previous cases suggest that
single anti-pseudomonal coverage is sufﬁcient. The preferential
choice of anti-pseudomonal agent is unknown, but should be
compatible with the organism’s sensitivity proﬁle in addition to
the patient’s clinical proﬁle, including allergies, kidney function,
and QT interval. In prior cases, treatment durations were a
minimum of 2 weeks.
Conclusion
Infections caused by P. stutzeri are far less frequent and less fatal
than those caused by P. aeruginosa. However, this organism has
been demonstrated to cause clinically signiﬁcant infections at
variable sites. Antimicrobial therapy with an anti-pseudomonal
agent should be guided by sensitivity proﬁles on an individual case
basis. Here, we presented two P. stutzeri infections, one of a
prosthetic vascular graft and another of a prosthetic joint. Our case
of P. stutzeri prosthetic vascular graft infection was successfully
treated with a single anti-pseudomonal agent for 6 weeks and the
removal of the infected vascular graft. Based on our and previous
cases of P. stutzeri joint infections, a single anti-pseudomonal agent
for at least 4–6 weeks is likely sufﬁcient. When considering the
source of a P. stutzeri infection, one should consider not onlyexposure to soil and water, but also the importance of immuno-
compromised states and potentially contaminated material in the
health care setting, as demonstrated by our presented cases.
Finally, considering the growing trend of health care tourism and
patients seeking care outside of North America, clinicians must be
aware of this organism and its signiﬁcant potential as a cause of
fever in the returned traveler.
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